Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical practice guidelines: renal cell carcinoma

R M Bukowski1, A C Novick

  • 1Experimental Therapeutics Program, Cleveland Clinic Cancer Center, Cleveland Clinic Foundation, OH 44195, USA.

Cleveland Clinic Journal of Medicine
|January 1, 1997
PubMed
Summary

Metastatic renal cell carcinoma (RCC) is difficult to treat. While surgery offers potential cure, immunotherapy with biologic response modifiers like interferon alfa shows promise for tumor regression in select patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

23 assessment of T-cell immune dysfunction in patients with renal cell carcinoma.

Methods in molecular medicine·2011
Same author

Graft outcomes of living donor renal transplantations in elderly recipients.

Transplantation proceedings·2008
Same author

Medical versus surgical management of atherosclerotic renal artery stenosis.

Transplantation proceedings·2002
Same author

The use of expanded criteria cadaver and live donor kidneys for transplantation.

The Urologic clinics of North America·2002
Same author

Long-term results of surgical revascularization for renal artery disease.

The Urologic clinics of North America·2002
Same author

Laparoscopic radical nephrectomy in 100 patients: a single center experience from the United States.

Cancer·2001

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Renal cell carcinoma (RCC) is the most common kidney cancer, with increasing global incidence.
  • Metastatic RCC is largely resistant to traditional chemotherapy, with poor survival rates.

Purpose of the Study:

  • To review and compare historical and current practice guidelines for RCC treatment.
  • To evaluate the efficacy of various therapeutic modalities for metastatic RCC.

Main Methods:

  • Review of existing data on RCC treatment modalities.
  • Analysis of outcomes associated with immunotherapy and combination therapies.

Main Results:

  • Surgery is the only potentially curative option for RCC.
  • Biologic response modifiers (BRMs), including interferon alfa, demonstrate objective tumor regression in some advanced RCC patients.
  • Immunotherapy with interferon alfa and interleukin-2 shows meaningful antitumor responses in selected patients.

Conclusions:

  • Performance status is a key predictor for treatment decisions in metastatic RCC.
  • Combination immunotherapy (interferon alfa, interleukin-2, 5-fluorouracil) shows promise.
  • Subcutaneous administration of immunotherapy may improve tolerability and convenience.

Related Experiment Videos